The distribution of a new cephalosporin, cefdinir, in serum, epithelial lining fluid (ELF), bronchial mucosa and alveolar macrophages was studied in 17 adults following a single oral dose of 300 or 600 mg of cefdinir; tissue samples being obtained by diagnostic bronchoscopy approximately 4 h after this dose. Mucosal biopsies were taken, alveolar macrophages harvested by lavage, and ELF volume derived from urea concentrations in bronchial lavage fluid and blood. A microbiological assay for cefdinir was performed in serum, bronchial mucosa, ELF and alveolar macrophages. In patients taking 300 mg of cefdinir, the median concentrations of cefdinir were 2.00 mg/L (range 1.40-8.00) in serum, 0.78 mg/L (range 0-1.33) in bronchial mucosa, and 0.29 mg/L (range 0-4.73) in ELF. In patients taking 600 mg, the median concentrations were 4.20 mg/L (range 3.05-6.40) in serum, 1.14 mg/L (range 0-1.92) in bronchial mucosa, and 0.49 mg/L (range 0-0.59) in ELF. Cefdinir did not penetrate macrophages.
Introduction
Cefdinir is a new, extended-spectrum, orally-active, semi-synthetic cephem (Inamoto et al., 1988) , with structural similarities to cefixime but with a hydroxyimino-aminothiazole side chain substituting the carboxymethoxyimino moiety (present in most orally-active cephalosporins) at the 7-position: this sterically hinders the entry of the molecule into the active site of TEM-1 /Mactamase, and also enhances its activity against Gram-positive bacteria (Beltran et al., 1992) .
Cefdinir is bactericidal in vitro against Streptococcus species, including Streptococcus pneumoniae (Roditi, Callan & Theron, 1991; Wise, Andrews & Thornber, 1991; Payne & Amyes, 1992) , against which its activity is intermediate between that of ampicillin and that of cefaclor (Benomar et al., 1991; Beltran et al., 1992) . It is highly active against methicillin-sensitive Staphylococcus aureus, showing a higher affinity for the penicillin-binding proteins of this species than cefixime, cefaclor or cephalexin (Bauernfeind et al., 1992) . It is also active against Haemophilus influenzae (including /Mactamase producing strains), Klebsiella pneumoniae, Moraxella catarrhalis and several other Gram-negative species including /Mactamase producing Escherichia coli (Neu, 1986) , but not Pseudomonas aeruginosa or Pseudomonas cepacia, and several species of anaerobic bacteria but not Bacteroides species . MIC* values for common respiratory pathogens are shown in Table I . In contrast to some P. J. Cook et at.
other cephalosporins, significant post-antibiotic effects have been demonstrated for Gram-negative as well as for Gram-positive bacteria (Howard & Smith, 1991) . Owing to its oximino side chain, it is highly stable in the presence of a wide range of penicillinases (including TEM-1, TEM-2 and SHV-1) and cephalosporinases, resembling cefixime in this respect , and is therefore suitable for the treatment of acute exacerbations of chronic bronchitis and bacterial pneumonia, as well as upper respiratory tract infections, uncomplicated urinary tract infections, skin and soft tissue infections.
Evidence from Pruul & McDonald (1993) showing an increased susceptibility of phagocytosed Escherichia coli and Staphylococcus aureus to killing by neutrophils in the presence of cefdinir at concentrations significantly below the MIGw suggests that cefdinir may have some activity against intracellular pathogens.
The anticipated adult dosage range for this antibiotic is 300-600 mg. Pharmacokinetic studies indicate that the mean time to reach maximum plasma concentration is 3.4 h after single oral doses of 50-600 mg, irrespective of dose (Guttendorf et al., 1991) . The mean time of maximum concentration in blister fluid is 4-5 h after single oral doses of 200-600 mg, irrespective of dose (Lebel et al., 1992) .
The objective of our study was to determine the distribution of cefdinir in plasma, bronchial mucosa and broncho-alveolar lavage fluid, 4 h after a single oral dose of 300 or 600 mg.
Methods
This was an open-label, non-blinded, randomised study. It was carried out between December 1993 and August 1994.
Patients
Seventeen patients (thirteen males and four post-menopausal females) were recruited. All were considered to need diagnostic bronchoscopy, either for haemoptysis or because of an abnormal chest x-ray. They had a mean age of 61.9 years (range 41-74) and mean weight of 69.0 kg (range 52.1-98.5). Exclusion criteria included a history of significant adverse reactions to /Mactam antibiotics, unstable cardio-vascular, gastro-intestinal, hepatic, renal, endocrine, haematological, neurological or psychiatric disease, current alcohol dependence or any history of drug abuse. Patients were also excluded if there was any clinical evidence of respiratory infection at the time of initial assessment. In view of a reported reduction in bioavailability of cefdinir after co-administration with ferrous sulphate, which chelates the antibiotic (Sakamoto et al., 1988) , they were not permitted to take iron-containing compounds during the 14 days before bronchoscopy.
Each patient underwent full clinical examination, haematological and biochemical (renal and hepatic) evaluation and urinalysis up to 7 days before bronchoscopy. Each gave fully informed written consent prior to entry into the study, whose protocol had been approved by the Ethics Committee of the hospital.
Medication
On the day before bronchoscopy, each patient was instructed to fast from 10.00 p.m. On arrival at the hospital, each patient took a single dose of one or two capsules by Table I . MIC« values for cefdinir against selected pathogens (Mine et al., 1988; Neu, Saha & Chin, 1989; van Griethuysen, 1992) mouth, each containing cefdinir 300 mg (expressed as active moiety). The capsules were swallowed intact, with 100 mL of water. The first two subjects received cefdinir 600 mg (two 300 mg capsules); thereafter, nine received 300 mg and six 600 mg, by random allocation (Tables II and III) . Bronchoscopy was performed approximately 4 h after oral dosing (range 182-260 min, median 224).
Bronchoscopy
A standard premedication of 600 /ig atropine was given by intramuscular injection 60 min before bronchoscopy, 4 mL of 4% lignocaine by nebuliser 40 min later, and up to 5 mg of midazolam intravenously at the time of bronchoscopy. At that time, up to 4 mL of 4% lignocaine was administered to the pharynx and vocal cords, and up to 6 mL of 2% lignocaine to the carina and main bronchi.
Broncho-alveolar lavage (BAL) was performed on each patient. The bronchoscope was wedged into the right middle lobe or the lingula, and 50 mL aliquots of sterile 0.9% sodium chloride solution, pre-warmed to 37°C, were instilled. The first aspirate of BAL fluid was discarded, so as to avoid contamination with cells and secretions from the proximal airways, and the next three aspirates (i.e. 150 mL) collected into a Teflon container (to which aspirated cells do not adhere significantly), using a suction pressure of 400-500 mmHg to prevent excessive mucosal trauma. (Approximately 50% of each aliquot was recovered by this technique.) Lavage time was reduced to a minimum (no more than 4 min), in order to limit the concentration-dependent efflux of solutes into BAL fluid. The total leucocyte count was estimated immediately using an improved Neubauer haemocytometer. Within 5 min of lavage, the pooled BAL fluid was centrifuged at 400# for 5 min: the supernatant was then freeze-dried and reconstituted in one-tenth of the original volume of distilled water, making a ten-fold concentration.
This preparation thus contained a volume of epithelial lining fluid, defined (for practical purposes) as the fluid that lines the terminal bronchioles, alveoli and alveolar macrophages.
Venous blood was collected within 5 min of bronchoscopy, placed immediately on ice and centrifuged at 1500# for 10 min at 4°C. Sera were separated immediately, and were diluted 1:10 and 1:20 with pooled antibiotic-free human serum before assay.
Assuming that urea is present at the same concentration in ELF and blood, the volume of ELF in broncho-alveolar lavage aspirate can be calculated from urea concentrations in BAL flud and serum (Rennard et al., 1986) and concentrations of antibiotics derived, as follows:
Within 1 h of collection, the cell pellet was homogenised by probe sonicator (Heat Systems Ultrasonic Inc., model W375) in a measured volume of cold phosphate buffer (pH 6.6) on ice. In health, approximately 95% of cells in the alveoli are alveolar macrophages (Walters & Gardiner, 1991) , whose mean volume has previously been estimated at 2.42 (S.E.M. 0.41) ^L/10 6 cells (Baldwin et al., 1991) . Superficial biopsies for antimicrobial assay were taken from macroscopically normal subcarinal sites i.e. without erythema, oedema, induration, or abnormal friability, before diagnostic biopsies. Visibly blood-stained specimens were discarded. The tissue was transferred immediately to a humidity chamber, weighed and homogenised within 1 h of collection as described above, in a known volume of phosphate buffer (pH 6.6) on ice.
Microbiological assay
Except in BAL fluid, all antibiotic assays were performed on the day of bronchoscopy.
All samples were assayed by a microbiological assay diffusion method employing Antibiotic Medium Number 1 (Unipath CM 327, Basingstoke, UK) and a Proteus rettgeri (J294) assay organism. An overnight broth culture of organism diluted in sterile distilled water to an optical density of 0.004 at a wavelength of 630 run was used to inoculate the surface of the agar. Calibrators were prepared from reference powder, adjusted for potency, in pooled human serum (Bradsure Biologicals, Market Harborough, Leicestershire) for the assay of serum samples, phosphate buffer (pH 6.6) for the assay of macrophages and biopsy tissue, and 9% sodium chloride for the assay of concentrated lavage (calibrator range 0.062, 0.125, 0.25, 0.5 and 1 mg/L). Internal controls of 0.1 and 0.8 mg/L were included on every assay plate. Samples were applied to the plate in a random pattern in triplicate, by filling 5 mm wells punched into the agar. After overnight incubation at 30°C, zones of inhibition were measured using a zone reader which magnified them x 8 (Leebrook Ltd, Strood, Kent, UK). Test and internal control concentrations were derived from a line of best fit constructed using Bennett's calculation (Bennett et al., 1966) .
The lower limit of detection was 0.03 mg/L and the between-assay coefficient of variation was 9.84%.
Follow-up
Physical examination and clinical laboratory measurements were performed at out-patient review 7-14 days after bronchoscopy.
Results
No adverse events attributable to antibiotic medication were observed at bronchoscopy, or reported by patients at out-patient review.
One of the 17 patients who received cefdinir did not undergo bronchoscopy; therefore only 16 gave samples for the analysis of antibiotic concentrations in pulmonary compartments. The concentration of cefdinir in ELF was not tested in one of these patients, because of technical difficulties.
The results are shown in Tables II and III . The median serum level in patients receiving cefdinir 300 mg was 2.0 mg/L, and in patients receiving 600 mg, 4.2 mg/L: this difference is significant at P = 0.016 (Mann-Whitney U test). The median levels in bronchial mucosa were 0.78 and 1.14 mg/L, and in ELF, 0.29 and 0.49 mg/L, respectively: these differences were not significant (P = 0.318, 0.682). Cefdinir was undetectable in macrophages in all but one patient.
Thus cefdinir achieved serum concentrations significantly above the MIG» for common respiratory pathogens in all 17 patients tested (range 1.40-8.00 mg/L). In bronchial mucosa, this level was exceeded in 14 of the 16 patients tested (range 0-1.92 mg/L, median 0.91); and in ELF, it was exceeded in 11 of the 15 patients tested (range 0-4.73 mg/L, median 0.39).
Discussion
A knowledge of the serum concentrations of antibiotics may be less useful than knowing their concentrations at the site of infection . For example, antibiotics that are concentrated in the urine may be effective in urinary infections, even where serum concentrations are significantly below the MIC90 for the responsible organism (Stamey et al., 1974) , while renal tissue concentrations accurately predict efficacy in ascending urinary infections (Fabre et al., 1976) . In the lung concentrations of antibiotics differ between discrete tissue compartments-submucosal connective tissue, alveolar epithelium, alveolar macrophages, epithelial lining fluid and sputum. The alveolar membrane is relatively impermeable to antibiotics, owing to the presence of tight junctions or zonulae occludentes (Taylor, Guyton & Bishop, 1965; Effros et al., 1988) , and the capillary endothelium which separates the alveolar submucosa from blood, being non-fenestrated (Staehelin, 1974) , is less permeable than the fenestrated capillaries of other organs (Kaibara & Kikkawa, 1971) . The antibiotic's pK., molecular weight, protein binding and lipid solubility also influence the rates of penetration and clearance (Bergogne-Berezin, 1981) .
In many pulmonary infections, bacteria are chiefly found within the lumen of the airways, at the mucosal cell surface and within bronchial mucosal tissue (Hers & Mulder, 1953) . The mucosa, epithelial lining fluid (ELF) and alveolar macrophages all appear to be important sites for host defence against invasion (Valcke, Pauwels & van der Straeten, 1990) .
At this stage, bacteria are separated from blood by significant barriers to antibiotic diffusion; though, in some cases, antibiotics may be secreted into the bronchial lumen by epithelial cells.
Broncho-alveolar lavage allows the measurement of antibiotic levels in epithelial lining fluid and alveolar macrophages, as well as in bronchial secretions, sputum and bronchial mucosa (European Society of Pneumology Task Group on BAL, 1989; BAL Co-operative Group Steering Committee, 1990) . Methods for measuring concentrations of solutes in ELF are complicated by the potential movement of solute and solvent across the alveolar-capillary membrane: dwell times must therefore be kept to a minimum (Baldwin, Honeybourne & Wise, 1992) . Our results show that cefdinir is taken up by bronchial mucosa and ELF, where it achieves concentrations which we would predict to be clinically useful for a range of respiratory pathogens. At both doses tested, the penetration of bronchial mucosa (31-41%) is similar to that reported for all other /Mactam antibiotics studied to date . Despite the significantly higher serum levels achieved after 600 mg than after 300 mg of the antibiotic, the concentrations measured in bronchial mucosa and ELF were not significantly different. Our failure to demonstrate the uptake of cefdinir by macrophages in either group is not surprising, since good intracellular penetration is not a feature of /Mactam antibiotics.
A clinical role for cefdinir in a wide range of pulmonary infections is suggested by these data. The prospect of high clinical efficacy against S. pneumoniae is of particular interest, in view of the rapid increase in penicillin-resistant isolates of S. pneumoniae throughout Europe and the United States.
